Get the latest Science News and Discoveries
Two complete responses and response rate of 41% for people with synovial sarcoma reported at ASCO in Adaptimmune's phase 2 SPEARHEAD-1 trial
None
Or read this on Eureka AlertGet the latest Science News and Discoveries
None
Or read this on Eureka AlertRead more on:
Related news: